Top 5 Integrated Utility Stocks To Watch Right Now

Top 5 Integrated Utility Stocks To Watch Right Now: ARIAD Pharmaceuticals Inc.(ARIA)

ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company?s lead cancer product, ridaforolimus is being studied in multiple clinical trials in patients with various types of cancers, including metastatic sarcomas, breast cancer, endometrial cancer, prostate cancer, and non-small cell lung cancer. Its product pipeline also includes ponatinib, a pan BCR-ABL inhibitor in phase 2 clinical trial for applications in various hematological cancers and solid tumors; and AP26113, an anaplastic lymphoma kinase inhibitor in preclinical studies for the treatment of various cancers, including non-small cell lung cancer, lymphoma, and neuroblastoma. In addition, the company focuses on a drug discovery program centered on small-molecule therapies that are molecularly targeted to cell-signaling pathways implicated in cancer. Further, it licenses its ARGENT cell-sign aling regulation technologies to pharmaceutical and biotechnology companies to develop and commercialize therapeutic products, and to conduct drug discovery research. The company has collaboration and license agreements with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus to prevent restenosis of injured vessels. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is based in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Ariad Pharmaceuticals (NASDAQ: ARIA) shot up 3.19 percent to $7.04. ARIAD will present at the JP Morgan Healthcare Conference on January 14 at 6:00 PM ET.

• [By David Williamson]

  In the following video, Motley Fool health-care analyst David Williamson d! iscusses Ariad Pharmaceuticals (NASDAQ: ARIA  ) , as the company's stock reverses direction today, up 3% following yesterday's tumble. He notes the results of a boutique institutional research survey that found Ariad's new drug Iclusig to have toxicity concerns, and even more negative information coming from the FDA, citing blood clots and liver toxicity. David tells investors what the potential for this drug is, and whether it has a shot at success on the market despite these safety concerns.

• [By Brian Orelli]

  Ariad Pharmaceuticals (NASDAQ: ARIA  ) is the biotech of the week on the Fool's weekly biotech-focused show, Biotech Banter.

  Shares of the biotech have been on a bit of a roller coaster over the last year as investors went from having high hopes for Ariad Pharmaceutical's leukemia drug Iclusig to seeing the drug getting pulled from the market because the drug is linked to blood clots. After returning to the market, Ariad's shares have more than doubled off their lows, but are still well off of where they were when investors thought Iclusig could compete with Novartis' (NYSE: NVS  ) Gleevec and Bristol-Myers Squibb's (NYSE: BMY  ) Sprycel as first-line treatments.

• [By Jason Shubnell]

  Ariad Pharmaceuticals (NASDAQ: ARIA) was also up, gaining 7.43 percent to $8.16 on a report from the UK Daily Mail that Jazz Pharmaceuticals is willing to pay $20.00 per share for the maker of Iclusig.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-5-integrated-utility-stocks-to-watch-right-now.html